Measuring adherence to therapy in airways disease

Joshua Holmes; Liam G. Heaney

doi:10.1183/20734735.0037-2021

Measuring adherence to therapy in airways disease

Joshua Holmes, Liam G. Heaney^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

21 Citations (Scopus)

138 Downloads (Pure)

Abstract

Non-adherence to medication is one of the most significant issues in all airways disease and can have a major impact on disease control as well as on unscheduled healthcare utilisation. It is vital that clinicians can accurately determine a patient’s level of adherence in order to ensure they are gaining the maximal benefit from their therapy and also to avoid any potential for unnecessary increases in therapy. It is essential that measurements of adherence are interpreted alongside biomarkers of mechanistic pathways to identify if improvements in medication adherence can influence disease control. In this review, the most common methods of measuring adherence are discussed. These include patient self-report, prescription record checks, canister weighing, dose counting, monitoring drug levels and electronic monitoring. We describe the uses and benefits of each method as well as potential shortcomings. The practical use of adherence measures with measurable markers of disease control is also discussed.

Original language	English
Article number	210037
Number of pages	9
Journal	Breathe
Volume	17
Issue number	2
DOIs	https://doi.org/10.1183/20734735.0037-2021
Publication status	Published - 23 Jun 2021

Bibliographical note

Funding Information:
J. Holmes has nothing to disclose. L.G. Heaney reports other (sponsorship for attending international scientific meetings) from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK and Napp Pharmaceuticals; personal fees (lecture fees and advisory boards) from Novartis, Hoffman la Roche/Genentech Inc, Sanofi, Evelo Biosciences, GlaxoSmithKline, AstraZeneca, Teva, Theravance and Circassia; institutional grant funding from Medimmune, Novartis UK, Roche/Genentech Inc, and GlaxoSmithKline, outside the submitted work. L.G. Heaney is Academic Lead for the Medical Research Council Stratified Medicine UK Consortium in Severe Asthma which involves Industrial Partnerships with Amgen, Genentech/Hoffman la Roche, AstraZeneca, Medimmune, GlaxoSmit Kline, Aerocrine and Vitalograph, outside the submitted work.

Publisher Copyright:
© 2021, European Respiratory Society. All rights reserved.

Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

Access to Document

10.1183/20734735.0037-2021Licence: CC BY-NC

Measuring adherence to therapy in airways disease
Copyright 2021 the authors. This is an open access Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits use, distribution and reproduction for non-commercial purposes, provided the author and source are cited.
Final published version, 119 KBLicence: CC BY-NC

Cite this

@article{58a53ac562884dc8865209b02b415f84,

title = "Measuring adherence to therapy in airways disease",

abstract = "Non-adherence to medication is one of the most significant issues in all airways disease and can have a major impact on disease control as well as on unscheduled healthcare utilisation. It is vital that clinicians can accurately determine a patient{\textquoteright}s level of adherence in order to ensure they are gaining the maximal benefit from their therapy and also to avoid any potential for unnecessary increases in therapy. It is essential that measurements of adherence are interpreted alongside biomarkers of mechanistic pathways to identify if improvements in medication adherence can influence disease control. In this review, the most common methods of measuring adherence are discussed. These include patient self-report, prescription record checks, canister weighing, dose counting, monitoring drug levels and electronic monitoring. We describe the uses and benefits of each method as well as potential shortcomings. The practical use of adherence measures with measurable markers of disease control is also discussed.",

author = "Joshua Holmes and Heaney, {Liam G.}",

note = "Funding Information: J. Holmes has nothing to disclose. L.G. Heaney reports other (sponsorship for attending international scientific meetings) from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK and Napp Pharmaceuticals; personal fees (lecture fees and advisory boards) from Novartis, Hoffman la Roche/Genentech Inc, Sanofi, Evelo Biosciences, GlaxoSmithKline, AstraZeneca, Teva, Theravance and Circassia; institutional grant funding from Medimmune, Novartis UK, Roche/Genentech Inc, and GlaxoSmithKline, outside the submitted work. L.G. Heaney is Academic Lead for the Medical Research Council Stratified Medicine UK Consortium in Severe Asthma which involves Industrial Partnerships with Amgen, Genentech/Hoffman la Roche, AstraZeneca, Medimmune, GlaxoSmit Kline, Aerocrine and Vitalograph, outside the submitted work. Publisher Copyright: {\textcopyright} 2021, European Respiratory Society. All rights reserved. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

month = jun,

day = "23",

doi = "10.1183/20734735.0037-2021",

language = "English",

volume = "17",

journal = "Breathe",

issn = "1810-6838",

publisher = "European Respiratory Society",

number = "2",

}

TY - JOUR

T1 - Measuring adherence to therapy in airways disease

AU - Holmes, Joshua

AU - Heaney, Liam G.

N1 - Funding Information: J. Holmes has nothing to disclose. L.G. Heaney reports other (sponsorship for attending international scientific meetings) from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK and Napp Pharmaceuticals; personal fees (lecture fees and advisory boards) from Novartis, Hoffman la Roche/Genentech Inc, Sanofi, Evelo Biosciences, GlaxoSmithKline, AstraZeneca, Teva, Theravance and Circassia; institutional grant funding from Medimmune, Novartis UK, Roche/Genentech Inc, and GlaxoSmithKline, outside the submitted work. L.G. Heaney is Academic Lead for the Medical Research Council Stratified Medicine UK Consortium in Severe Asthma which involves Industrial Partnerships with Amgen, Genentech/Hoffman la Roche, AstraZeneca, Medimmune, GlaxoSmit Kline, Aerocrine and Vitalograph, outside the submitted work. Publisher Copyright: © 2021, European Respiratory Society. All rights reserved. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/6/23

Y1 - 2021/6/23

N2 - Non-adherence to medication is one of the most significant issues in all airways disease and can have a major impact on disease control as well as on unscheduled healthcare utilisation. It is vital that clinicians can accurately determine a patient’s level of adherence in order to ensure they are gaining the maximal benefit from their therapy and also to avoid any potential for unnecessary increases in therapy. It is essential that measurements of adherence are interpreted alongside biomarkers of mechanistic pathways to identify if improvements in medication adherence can influence disease control. In this review, the most common methods of measuring adherence are discussed. These include patient self-report, prescription record checks, canister weighing, dose counting, monitoring drug levels and electronic monitoring. We describe the uses and benefits of each method as well as potential shortcomings. The practical use of adherence measures with measurable markers of disease control is also discussed.

AB - Non-adherence to medication is one of the most significant issues in all airways disease and can have a major impact on disease control as well as on unscheduled healthcare utilisation. It is vital that clinicians can accurately determine a patient’s level of adherence in order to ensure they are gaining the maximal benefit from their therapy and also to avoid any potential for unnecessary increases in therapy. It is essential that measurements of adherence are interpreted alongside biomarkers of mechanistic pathways to identify if improvements in medication adherence can influence disease control. In this review, the most common methods of measuring adherence are discussed. These include patient self-report, prescription record checks, canister weighing, dose counting, monitoring drug levels and electronic monitoring. We describe the uses and benefits of each method as well as potential shortcomings. The practical use of adherence measures with measurable markers of disease control is also discussed.

U2 - 10.1183/20734735.0037-2021

DO - 10.1183/20734735.0037-2021

M3 - Review article

AN - SCOPUS:85109168223

SN - 1810-6838

VL - 17

JO - Breathe

JF - Breathe

IS - 2

M1 - 210037

ER -

Measuring adherence to therapy in airways disease

Abstract

Bibliographical note

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this